⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 3, 2026European Heart Journal - Quality of Care and Clinical Outcomes

Sodium-glucose cotransporter 2 inhibitors across cardio-reno-metabolic disease and body mass index: a meta-analysis of randomized controlled trials

Dimitrios Farmakis Konstantinos Karampinos Chris J Kapelios Sotiria Liori Katerina Fountoulaki Gerasimos Filippatos

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the effects of SGLT2 inhibitors on cardiovascular outcomes across various body mass indices.
Conducted a meta-analysis of randomized controlled trials
Included diverse cardiovascular and renal populations
Analyzed outcomes related to cardiovascular death and hospitalization
SGLT2 inhibitors significantly reduced cardiovascular death and heart failure hospitalization
These benefits were observed across all body mass index categories
Overall mortality was also reduced with SGLT2 inhibitors

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Meta-analysis shows SGLT2 inhibitors reduce cardiovascular death in all BMI groups, suggesting broad benefit.

Abstract

Across a broad CRM population, SGLT2i reduce cardiovascular death or HF hospitalization and all-cause death irrespective of BMI.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Farmakis et al. (2026) studied this question.

synapsesocial.com/papers/69d895ea6c1944d70ce07133 https://doi.org/10.1093/ehjqcco/qcag061

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Sodium–glucose cotransporter-2 inhibitors in heart failure patients across the range of body mass index: a systematic review and meta-analysis of randomized controlled trialsmeta-analysis · 2024 · 9 citations
2Safety and Efficacy of Sodium Glucose Cotransporter-2 Inhibitors in Patients With Cancer and Diabetes.Human Clinical Trial · 2026
3SGLT2 inhibitors for prevention of primary and secondary cardiovascular outcomes: A meta-analysis of randomized controlled trialsMeta-Analysis · 2023 · 38 citations
4Update on the Efficacy and Safety of Sodium–Glucose Co-Transporter 2 Inhibitors in Patients with Chronic Diseases: A Systematic Review and Meta-AnalysisRCT · 2025 · 25 citations
5Cardiovascular Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Updated Meta-AnalysisMeta-Analysis · 2024 · 6 citations

Effects of sodium-glucose co-transporter-2 inhibitors on anthropometric indices and metabolic markers in overweight/obese individuals without diabetes: a systematic review and meta-analysis2022
The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis2021
Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: An Updated Meta-Analysis2022
Proteinuria in treated hypertension: closing the gap between detection and careEuropean Heart Journal - Quality of Care and Clinical Outcomes · 2026
The complexity of congestion in heart failure: a critical review of the evidence and a proposal for a multimodality approachEuropean Heart Journal - Quality of Care and Clinical Outcomes · 2026

More from European Heart Journal - Quality of Care and Clinical Outcomes

More from National and Kapodistrian University of Athens